ClinicalTrials.Veeva

Menu
The trial is taking place at:
U

University of Massachusetts Chan Medical School | Medicine Department - Rheumatology Division

Veeva-enabled site

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

S

Sutro Biopharma

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Ovarian Cancer
Platinum-resistant Ovarian Cancer

Treatments

Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim
Drug: Topotecan
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Study type

Interventional

Funder types

Other
NETWORK
Industry

Identifiers

NCT05870748
GEICO-134-O (Other Identifier)
STRO-002-GM3
GOG-3086 (Other Identifier)
ENGOT-OV79 (Other Identifier)
APGOT-OV9 (Other Identifier)

Details and patient eligibility

About

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Full description

This is a randomized, multicenter, international, open-label, 2-part, Phase 2/3 study designed to assess the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1.

Part 1 will consist of 2 luveltamab tazevibulin dosing cohorts (Cohort A and Cohort B), with subjects randomized 1:1. Part 1 will be used to select the optimized dosing regimen.

Part 2 will further evaluate the efficacy and safety of the selected dosing regimen versus IC chemotherapy.

Luveltamab tazevibulin will be administered intravenously (IV) over a 1-hour infusion time every 3 weeks.

Enrollment

600 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. High grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  2. Age ≥ 18 years
  3. ECOG performance status 0 to 1
  4. Positive FOLR1 expression per central laboratory testing
  5. Relapsed platinum-resistant epithelial ovarian cancer and received a total of 1 to 3 prior regimens
  6. Prior bevacizumab treatment is required, if labeled and available as standard of care per institutional guidelines, unless subject has documented contraindication
  7. At least 1 measurable target lesion per RECIST v1.1
  8. Adequate organ function

Exclusion criteria

  1. Low grade (Grade 1) ovarian carcinoma, clear cell, mucinous, endometrioid, sarcomatous, and mixed histology ovarian carcinomas
  2. Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
  3. Primary platinum-refractory disease
  4. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
  5. Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  6. Previous solid organ transplantation
  7. History or clinical signs of meningeal or active central nervous system involvement
  8. Concurrent participation in another therapeutic treatment trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

600 participants in 3 patient groups

Luveltamab tazevibulin dose Cohort A
Experimental group
Description:
5.2 mg/kg q3w with prophylactic pegfilgrastim for 2 cycles followed by 4.3 mg/kg q3w for Cycle 3 onwards
Treatment:
Drug: Pegfilgrastim
Drug: Luveltamab tazevibulin
Luveltamab tazevibulin dose Cohort B
Experimental group
Description:
4.3 mg/kg q3w
Treatment:
Drug: Luveltamab tazevibulin
Part 2: IC Chemotherapy
Active Comparator group
Description:
Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 q4w or 1000mg/m2 on Days 1 and 8 q3w Paclitaxel 80 mg/m2 on Days 1, 8, and 15 q4w Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 q4w Topotecan 4.0 mg/m2on Day 1, 8, and 15 q4w or 1.25 mg/m2 on Days 1 - 5 q3w
Treatment:
Drug: Pegylated liposomal doxorubicin
Drug: Paclitaxel
Drug: Topotecan
Drug: Gemcitabine

Trial contacts and locations

38

Loading...

Central trial contact

Craig Berman, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems